Prednisolone phosphate API Manufacturers

General Description:

Prednisolone phosphate, identified by CAS number 302-25-0, is a notable compound with significant therapeutic applications. Prednisolone phosphate is a glucocorticoid similar to used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone phosphate was granted FDA Approval on 19 December 1973.

Indications:

This drug is primarily indicated for: Prednisolone phosphate is indication to a number of conditions including treat allergic states, dermatologic diseases, edematous states, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system, ophthalmic diseases, respiratory diseases, rheumatic disorders. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Prednisolone phosphate undergoes metabolic processing primarily in: Prednisolone phosphate undergoes ester hydrolysis to . After this step, the drug undergoes the normal metabolism of prednisolone. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Prednisolone phosphate are crucial for its therapeutic efficacy: A 30mg prednisolone oral solution reaches a C_max of 461.33±77.94ng/mL with an AUC of 2426.1±360.0ng\*h/mL. A 30mg prednisolone orally disintegrating tablet reaches a C_max of 420.91±78.28ng/mL with an AUC of 2408.1±361.5ng\*h/mL. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Prednisolone phosphate is an important consideration for its dosing schedule: The half life of prednisolone is 2-4 hours. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Prednisolone phosphate exhibits a strong affinity for binding with plasma proteins: Prednisolone is 70-90% protein bound in plasma. Prednisolone typically binds to albumin and corticosteroid binding globulin. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Prednisolone phosphate from the body primarily occurs through: Prednisolone is predominantly eliminated in the urine as sulfate and glucuronide conjugate metabolites. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Prednisolone phosphate is distributed throughout the body with a volume of distribution of: The volume of distribution of prednisolone phosphate has been reported as 0.22-0.7L/kg. This metric indicates how extensively the drug permeates into body tissues.

Pharmacodynamics:

Prednisolone phosphate exerts its therapeutic effects through: Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisolone has a short duration of action as the half life is 2-4 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Prednisolone phosphate functions by: The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Prednisolone phosphate belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety, classified under the direct parent group Gluco/mineralocorticoids, progestogins and derivatives. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Steroids and steroid derivatives class, specifically within the Pregnane steroids subclass.

Categories:

Prednisolone phosphate is categorized under the following therapeutic classes: Adrenal Cortex Hormones, Adrenals, Anti-Inflammatory Agents, Corticosteroids, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Substrates, P-glycoprotein inducers, P-glycoprotein substrates, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.